Symbicort vs Xolair
A side-by-side look at two respiratory medications advertised on TV. Informational only — not medical advice.
| US Symbicort | US Xolair | |
|---|---|---|
| Generic name | budesonide/formoterol | omalizumab |
| Drug class | ICS/LABA Inhaler | Anti-IgE Monoclonal Antibody |
| Treats | Asthma, COPD | Allergic asthma, chronic hives, food allergy |
| Category | Respiratory | Respiratory |
| Manufacturer | AstraZeneca | Genentech/Novartis |
| Year approved | 2006 | 2003 |
| FDA warning | No boxed warning | Black box warning |
| Est. TV ad spend | $120M | $95M |
| Common side effects | Throat irritation, Oral thrush, Hoarseness, Headache | Anaphylaxis (severe allergic reaction), Injection site reactions, Joint pain, Headache |
Frequently asked questions
Is Symbicort or Xolair better?
Neither is universally "better." Symbicort (budesonide/formoterol) and Xolair (omalizumab) are both used for respiratory, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Symbicort and Xolair?
Symbicort is a ICS/LABA Inhaler made by AstraZeneca, while Xolair is a Anti-IgE Monoclonal Antibody made by Genentech/Novartis. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Symbicort has the larger estimated TV advertising budget of the two.